Spots Global Cancer Trial Database for Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Official Title: Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Study ID: NCT00247663
Interventions
Study Description
Brief Summary: - To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Amagasaki, Hyogo, Japan
Novartis Investigative Site, Hamamatsu, Shizuoka, Japan
Novartis Investigative Site, Chuo-Ku, Tokyo, Japan
Novartis Investigative Site, Cyuo-ku, Tokyo, Japan
Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan
Novartis Investigative Site, Fukuoka, , Japan
Novartis Investigative Site, Kumamoto, , Japan
Novartis Investigative Site, Nigata, , Japan
Novartis Investigative Site, Saitama, , Japan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
